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Abstract
Aims/hypothesis Autoreactive B cells escape immune tolerance and contribute to the pathogenesis of type 1 diabetes. While
global B cell depletion is a successful therapy for autoimmune disease, the fate of autoreactive cells during this treatment in
autoimmune diabetes is unknown. We aimed to identify and track anti-insulin B cells in pancreatic islets and understand their
repopulation after anti-CD20 treatment.
Methods We generated a double transgenic system, the VH125.hCD20/NOD mouse. The VH125 transgenic mouse, expressing
an increased frequency of anti-insulin B cells, was crossed with a human CD20 (hCD20) transgenic mouse, to facilitate B cell
depletion using anti-CD20. B cells were analysed using multiparameter and ImageStream flow cytometry.
Results We demonstrated that anti-insulin B cells were recruited to the pancreas during disease progression in VH125.hCD20/
NOD mice. We identified two distinct populations of anti-insulin B cells in pancreatic islets, based on CD19 expression, with
both populations enriched in the CD138int fraction. Anti-insulin B cells were not identified in the plasma-cell CD138hi fraction,
which also expressed the transcription factor Blimp-1. After anti-CD20 treatment, anti-insulin B cells repopulated the pancreatic
islets earlier than non-specific B cells. Importantly, we observed that a CD138intinsulin+CD19− population was particularly
enriched after B cell depletion, possibly contributing to the persistence of disease still observed in some mice after anti-CD20
treatment.
Conclusions/interpretation Our observations may indicate why the loss of C-peptide is only temporarily delayed following anti-
CD20 treatment in human type 1 diabetes.
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Abbreviations
APC Antigen-presenting cell
BAFF B cell activating factor
BCR B cell receptor
CXCR3 C-X-C motif chemokine receptor 3
GMFI Geometric mean fluorescent intensity
hCD20 Human CD20
mAb Monoclonal antibody
PLN Pancreatic lymph node
Introduction
Type 1 diabetes is an organ-specific autoimmune disease
characterised by immune-mediated beta cell destruction in
pancreatic islets, which results in deficient insulin production.
Although Tcells directly damage insulin-producing beta cells,
B cells are key in this multifactorial process. Rituximab treat-
ment (B cell depletion therapy) in individuals with type 1
diabetes delayed loss of C-peptide in the first year after diag-
nosis [1]. Furthermore, B cell depletion in NODmice restored
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normoglycaemia in a proportion of diabetic mice [2, 3] and
improved islet allograft survival rate [4].
However, global B cell depletion may induce unwanted
side effects [5] and specific B cell targeting may be safer. In
this context, rituximab specifically suppressed anti-insulin
autoantibodies more than other autoantibodies [6]. Animal
studies have shown anti-insulin B cells are important in the
pathogenesis of type 1 diabetes. A B cell transgenic mouse,
expressing a fixed heavy-chain B cell receptor (BCR) with
potential for insulin binding, had an increased frequency of
anti-insulin B cells in a polyclonal repertoire (VH125) and
accelerated diabetes onset [7]. Conversely, the control
heavy-chain transgenic mouse (VH281), with restricted
insulin binding, had a reduced diabetes incidence [7].
Furthermore, anti-insulin B cell depletion using the mAb123
antibody in NODmice protected against spontaneous diabetes
[8]. Thus, autoreactive anti-insulin B cells play a particularly
important role in the pathogenesis of type 1 diabetes.
Although self-reactive B cells undergo central tolerance in
the bone marrow, autoantigen-specific B cells are found in the
peripheral B cell repertoire, in a functionally silent or anergic
state [9]. Anti-insulin B cells (125Tg model) have impaired
responses to both innate and adaptive B cell stimulators such
as lipopolysaccharide and anti-CD40, respectively [10].
However, these B cells can still present antigen and stimulate
both naive and insulin-specific CD4 T cells [11], suggesting
that even in an impaired state, autoreactive B cells can still
promote type 1 diabetes.
B1 B cells are important players in initiation of disease [12]
and are present early in the pancreas of NOD [12, 13] and
DO11xRIP-mOVA mice [12–14], whereas established islet
B cells have a more follicular phenotype [14], although anti-
gen specificity has not been investigated. Anti-insulin B cells
have been clearly identified in pancreatic islets of NOD mice
and are enriched at this site, compared with secondary lym-
phoid organs [15]. The aim of our study was to track the fate
of anti-insulin B cells in the pancreatic islets after anti-CD20
treatment by using a double transgenic NODmouse. Here, we
have focused specifically on the phenotype and functionality
of insulin-binding cells in the pancreatic islets, a tissue that is
not accessible in humans at specific times in the pathogenesis
of diabetes.
Methods
Mice NOD/Caj mice, originally from Yale University, were
bred in-house at Cardiff University. VH125/NODB cell trans-
genic mice [NOD.Cg-Tg(Igh-6/Igh-V125)2Jwt/JwtJ] and
VK125/NOD B cell transgenic mice [NOD.Cg-Tg(Igk-C/
Igk-V1251)Jwt/JwtJ] were purchased from the Jackson
Laboratory [7]. Mice were inter-crossed to generate 125Tg
mice. Human CD20 (hCD20) transgenic mice (BALB/c back-
ground), were backcrossed to NOD mice more than ten gen-
erations, and designated hCD20/NOD mice [2]. These mice
were crossed with VH125/NOD B cell transgenic mice to
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generate VH125.hCD20/NODmice. TheG9Cα−/−NODmice
[16] were bred in-house at Cardiff University. All mice re-
ceived water and irradiated food ad libitum and were housed
in specific-pathogen-free isolators or scantainers, with a 12 h
dark–light cycle, at Cardiff University. All animal experi-
ments were approved by Cardiff University ethical review
process and conducted under UK Home Office licence in
accordance with the UK Animals (Scientific Procedures)
Act, 1986 and associated guidelines.
Cell preparations Pancreatic lymph nodes (PLNs) were
disrupted mechanically with a 30G needle. Bone marrow cells
were flushed from the hind femur and tibia. Spleens were
homogenised and erythrocytes were lysed. Pancreases were
inflated with collagenase P solution (Roche, Welwyn Garden
City, UK) in HBSS via the common bile duct, followed by
collagenase digestion with shaking at 37°C for 10 min. Islets
were isolated by Histopaque density centrifugation (Sigma-
Aldrich, Dorset, UK), hand-picked under a dissecting micro-
scope and then trypsinised to generate a single-cell suspen-
sion. Islet cells were rested at 37°C 5% CO2 in complete
Iscove Modified Dulbecco’s Medium (IMDM) overnight.
Anti-insulin B cell detectionAnti-insulin B cells were detected
using recombinant human insulin–FITC (Sigma-Aldrich). For
flow cytometric analysis, B cells were incubated with
1.25 μg/ml insulin–FITC, together with surface receptor anti-
bodies, as described below. To ensure specific insulin binding,
a competitive assay was performed alongside experimental
tubes using non-labelled insulin (Sigma-Aldrich) at
25 μg/ml (20×). For detection of islet anti-insulin B cells,
the cells were incubated with insulin–FITC for 1 h at 37°C.
Flow cytometry Cells were incubated with TruStain (anti-
mouse CD16/32; Biolegend, London, UK) for 10 min at
4°C, followed by fluorochrome-conjugated monoclonal anti-
bodies (mAbs) against cell surface markers for 30 min at 4°C.
Multivariable flow cytometry was carried out using mAbs:
CD3 (145-2C11), B220 (RA3-6B2), IgD (11-26c.2a),
CD138 (281-2), CD86 (PO3), CD80 (16-10A1), CD11c
(N418), CD11b (M1/70), CD5 (53-7.3), hCD20 (2H7) and
mCD20 (SA271G2) purchased from Biolegend; CD21
(7G6), CD69 (H1.2F3), CD43 (S7) and IgMa (DS-1) pur-
chased from BD Biosciences (Wokingham, UK); CD19
(eBio1D3) and CD23 (B3B4) purchased from eBioscience
(San Diego, CA, USA) and CD220 (FAB1544P) purchased
from R&D systems (Abingdon, UK). Dead cells were exclud-
ed from analysis by Live/Dead exclusion dye (Invitrogen,
Paisley, UK). For intracellular cytokine staining, cells were
stimulated with phorbal 12-myristrate-13-acetate (PMA)
(50 ng/ml), ionomycin (500 ng/ml) and monensin (3 μg/ml)
(all from Sigma-Aldrich) for 3 h. After extracellular staining,
cells were fixed using a fixation/permeabilisation kit (BD
Biosciences) according to manufacturer’s instructions and
subsequently stained for intracellular cytokines (IFNγ
[XMG1.2], Biolegend) or with appropriate isotype controls.
For Blimp-1 (5E7; BDBiosciences) staining, cells were fixed/
permeabilised using eBioscience nuclear transcription kit.
Cell suspensions were acquired on an LSRFortessa
(FACSDIVA software, BD Biosciences) and analysed using
Flowjo software, version 10.1 (Tree Star, Ashland, OR, USA).
Anti-CD20 treatment Female VH125.hCD20/NOD mice,
6–8 weeks of age were chosen at random to receive either
anti-hCD20 antibody (clone 2H7; Bio-XCell, West Lebanon,
NH, USA) or control IgG2b antibody (clone MPC-11; Bio-
XCell [2, 17, 18]), as described previously [19]. The treatment
comprised four injections at intervals of 3 days, each contain-
ing 500 μg of antibody in 200 μl of saline (NaCl 154 mmol/l),
the first of which was i.v., followed by three i.p. injections.
Functional assay Anti-insulin B cells from VH125.hCD20/
NOD mice were labelled with insulin–FITC conjugate and
enriched using FITC microbeads (Miltenyi Biotec, Bisley,
UK), according to manufacturer’s instructions. The purity of
the enriched fraction ranged from 25–45% insulin binding. B
cells from both the insulin-negative and insulin-positive frac-
tion were stimulated with 5 μg/ml anti-CD40 (Bio-Xcell) for
24 h. Splenic CD8+ Tcells from G9Cα−/−mice were prepared
using CD8+ Tcell isolation kits (Miltenyi Biotec) and cultured
with B cell fractions (1:3 ratio). After 24 h, activation markers
were examined by flow cytometry.
Imagestream analysis Single cells from rested islets or
splenocytes were surface-stained and fixed as described above.
Fluorescent images were collected using INSPIRE software on
an Amnis Imagestream (Merck, Kenilworth, NJ, USA) imaging
flow cytometer, with a minimum of 50,000 cells per sample, and
analysed using Amnis IDEAS software (Merck).
Statistics Statistical analyses were performed using GraphPad
Prism (GraphPad Software, San Diego, CA, USA).
Significance was determined by one-way ANOVA followed
by a Dunn’s multiple comparison, or two-way ANOVA
followed by a Bonferroni post hoc test for more than two
variables and a Mann–Whitney U test for only two variables.
Data were significant at p < 0.05.
Results
Characterisation of anti-insulin B cells in VH125.hCD20/NOD
mice VH125/NOD transgenic mice expressing an increased
frequency of anti-insulin B cells [7] were crossed with
hCD20/NODmice [2] to generate VH125.hCD20/NODmice,
facilitating the depletion of B cells using the 2H7 mAb
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(depletes B cells expressing human CD20). Expression of
single or double transgenes did not affect T and B cell devel-
opment (ESM Fig. 1a,b). However, we noted an increase in
splenic marginal zone B cells when the VH125 transgene was
present, as previously reported [20] (ESM Fig. 1c).
We examined anti-insulin B cells using FITC-conjugated
insulin in four transgenic mouse strains (hCD20/NOD,
VH125 and VH125.hCD20/NOD mice and 125Tg mice
[transgenic for both heavy (VH) and light (VL) chains of the
125 insulin-specific BCR] as a positive control [21]).We dem-
onstrated an increased percentage of anti-insulin B cells in the
spleen of both VH125 and VH125.hCD20/NOD mice com-
pared with hCD20.NODmice (Fig. 1a,b). Anti-insulin B cells
populating all splenic compartments in the VH125.hCD20/
NOD mice (Fig. 1c–e), were comparable with anti-insulin B
cells that escape central tolerance in the spleen in VH125mice
[8]. Anti-insulin B cells were proportionally enriched in the
T2 population (CD21hiCD23hi) (Fig. 1d), which plays a role in
a hCD20 VH125.hCD20VH125 125Tg
b
C
D
19
Insulin
c
C
D
19
Insulin
d
B
22
0
Insulin
Pre-enrichment Negative fraction Positive fraction
f
g h
FO MZ T2
e
i
50.5
49.3 0.011 50.1 0.18 41.5 0.024 68.7 0.42
0.15 49.2 0.50 57.7 0.76 1.91 29.0
100
80
60
40
20
5
4
3
2
1
0
***
In
su
lin
+
 B
 c
el
l (
%
)
In
su
lin
+
 B
 c
el
l n
um
be
rs
hC
D2
0
VH
12
5.h
CD
20
12
5T
g
VH
12
5
98.2 1.75 98.3 1.60 95.4 4.64
8
6
4
2
0
In
su
lin
+
 B
 c
el
ls
 (
%
) ** **
FO
In
su
lin
-  B
 ce
lls
In
su
lin
+ B 
ce
lls
In
su
lin
-  B
 ce
lls
In
su
lin
+ B 
ce
lls
CD
80
CD
86
M
HC
 I
M
Z T2 FO M
Z T2
200,000
150,000
100,000
50,000
0
***
*
1.98 0.73 37.6
25
20
10
5
0
15
C
D
8+
C
D
69
+
 (
%
)
C
D
8+
IF
N
-γ
 +  
(%
)
In
su
lin
 b
in
di
ng
/n
on
-in
su
lin
bi
nd
in
g 
fo
ld
 c
ha
ng
e 
(G
M
F
I)
** 4
2
1
0
3
3
2
1
0
Fig. 1 Anti-insulin B cells successfully present antigen to insulin-specific
CD8 T cells. (a, b) Anti-insulin B cells from spleens of hCD20/NOD
(hCD20), VH125, VH125.hCD20/NOD (VH125.hCD20) and 125Tg
mice analysed by flow cytometry using human insulin conjugated to
FITC fluorochrome. Representative flow cytometric plots (a) and quan-
tification of total frequency of insulin-positive B cells (b) in each trans-
genic strain are shown. n = 6 (hCD20/NOD); n = 13 (VH125); n = 15
(VH125.hCD20/NOD); n = 18 (125Tg). Cells were gated on live
CD3−CD19+ cells. (c–e) VH125.hCD20/NOD splenic B cells were la-
belled for compartments (follicular zone [CD23hiCD21lo], marginal zone
[CD23loCD21hi], transitional 2 cells [CD23hiCD21hi]) and counterstained
with insulin–FITC (n = 8 mice). Representative flow cytometric plots of
insulin+ B cells in each compartment (c), quantification of the percentage
of B cells (d) and quantification of absolute insulin+ B cell numbers (e)
are shown. (f–i) Anti-insulin B cells from spleens of groups (n = 3–5
pooled) of VH125.hCD20/NOD mice were enriched using insulin–
FITC labelling and FITC microbeads and stimulated with 5 mg/ml anti-
CD40 for 24 h before co-culture with purified G9Cα−/− insulin-specific
CD8 T cells. CD8 T cells were then analysed for activation markers after
24 h. Positive insulin fractions after enrichment ranged from 25% to 45%
(n = 4 groups). Representative plots showing enrichment of insulin-bind-
ing B cells by anti-FITC microbeads, labelled with B220 (as B220-based
enrichment) and insulin (f) and the percentage of CD69 (g) and IFN-γ (h)
expression on live CD8 T cells after culture with insulin-positive and
-negative fractions are shown. (i) Fold change in GMFI of co-stimulation
markers CD80 and CD86 andMHC I on insulin-positive and -negative B
cells (live CD19+) after co-culture. All data shown are representative of at
least three independent experiments. Horizontal lines represent median
values. *p < 0.05, **p < 0.01 and ***p < 0.001 (one-way ANOVA) in (b,
d, e). **p < 0.01 (Mann–Whitney U test) in (g). FO, follicular zone; MZ,
marginal zone; T2, transitional 2
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antigen-specific positive selection as these cells proliferate
upon BCR engagement [22]. The absolute number of anti-
insulin B cells was significantly higher in both follicular and
marginal zones (Fig. 1e), sites where BCR signalling is fun-
damental for B cell maturity [23].
Anti-insulin B cells can successfully present antigen to insulin-
specific CD8+ T cells To assess functionality, we investigated
whether anti-insulin B cells could present insulin to and
activate insulin-specific CD8+ T cells from the monoclonal
G9Cα−/− CD8+TCR transgenic mouse. To obtain sufficient
anti-insulinB cells, we used a two-step enrichment approach
of insulin–FITC detection and anti-FITC microbeads (Fig.
1f).We obtained approximately 20 timesmore anti-insulinB
cells (Fig. 1f) compared with the multi-step biotinylated
antibody technique used by Smith et al [24] whereby enrich-
ment was approximately 8%. Insulin-positive and insulin-
negative fractions were then cultured with G9Cα−/− CD8+
T cells for 24 h. Significant CD69 upregulation (p = 0.026)
and increased IFN-γ (p = 0.114, not statistically significant)
production from CD8+ T cells was observed, when cultured
with insulin-positiveB cells comparedwith insulin-negative
B cells (Fig. 1g,h). Insulin-positive B cells cultured with
G9Cα−/−CD8+Tcells expressed increasedCD86 (geometric
mean fluorescent intensity [GMFI], p = 0.0571) when com-
pared with insulin-negative B cells (Fig. 1i). We also
observed a non-significant increase in the GMFI of CD80
and MHC I (Fig. 1i). Thus, anti-insulin B cells can success-
fully present to and activate IS-CD8+ T cells, corroborating
previous studies demonstrating that anti-insulin B cells,
despite being tolerant to antigen, are effective antigen-
presenting cells (APCs) [11].
Selective recruitment of anti-insulin B cells to pancreatic islets
We studied anti-insulin B cells in PLNs and pancreatic islets
from VH125.hCD20/NOD mice of different ages (Fig. 2). To
demonstrate specific binding to insulin, we performed a com-
petitive binding assay [7]. B cells from spleen, PLNs and
pancreatic islets were stained with insulin–FITC in the pres-
ence of human insulin (Fig. 2a). Successful inhibition of
insulin binding on B cells was found in all tissues (ESM
Fig. 2b); there was less inhibition in the PLNs (50%), in keep-
ing with insulin-binding B cells in the NOD PLNs having
different binding specificities [25]. We ensured that insulin
BCR staining was not due to increased insulin receptors on
B cells (ESM Fig. 2c), as anti-insulin receptor staining
(CD220) did not compete with insulin–FITC detection.
Next, we examined mice with a fully mature B cell reper-
toire developing early insulitis (aged 6–8 weeks old) and long-
established insulitis (18–20 weeks old). We demonstrated a
significantly increased frequency of anti-insulin B cells in
pancreatic islets (p < 0.05) and a non-significant increase in
the PLNs (p = 0.109); this appeared to coincide with disease
progression (Fig. 2b). We compared the number of anti-
insulin B cells in the PLNs and islets with numbers of B cells
that were not specific for insulin and showed selective
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Fig. 2 Anti-insulin B cells are selectively recruited to the pancreatic is-
lets. PLNs and pancreatic islets were analysed for the frequency of insu-
lin-positive B cells in VH125.hCD20/NOD mice aged 6–8 weeks (n = 5
mice) and 18–20 weeks (n = 8 mice [PLNs]; n = 12 mice [islets]). Cells
were gated on live CD3−CD19+ populations. (a) Flow cytometric plots
showing insulin staining in spleen, PLNs and pancreatic islets and com-
petitive binding assay with excess (20×) unlabelled insulin. (b) Numbers
of insulin-positive B cells from mice aged 6–8 weeks and 18–20 weeks
from both PLNs and pancreatic islets. (c) Ratio of insulin-positive to
insulin-negative B cells in PLNs and pancreatic islets in mice of different
ages, compared with spleen (pooled ages, n = 17 mice). Horizontal lines
represent median values. Data are representative of at least two indepen-
dent experiments. *p < 0.05 (one-way ANOVA)
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recruitment of anti-insulin B cells to the islets (spleen vs islets,
p < 0.05), whereas the absolute number of anti-insulin B cells
was unchanged in the spleen (Fig. 2c). These data suggested
that anti-insulin B cells are recruited to the target tissue during
beta cell destruction. This was also shown recently [26] and
supports the notion that anti-insulin B cells contribute to type
1 diabetes [7].
Established pancreatic islet B cells are heterogeneous early-
differentiated plasma-cell populations To investigate total
islet-infiltrating B cell population in our transgenic model,
we assessed islet B cells from VH125.hCD20/NOD and
NOD mice aged 12–20 weeks (Fig. 3). B cells from
VH125.hCD20/NOD mice were IgM+IgD−, whereas in
wild-type NOD islets, B cells were IgMlowIgD+ cells (Fig.
3a). During established insulitis, B cells become CD5 nega-
tive [12, 14] and upregulate CD138 [27]. We observed few
CD11b+ or CD5+ cells in both NOD and VH125.hCD20/
NOD mice, confirming that few B1a B cells were present
during insulitis (Fig. 3a).
We defined four subpopulations based on CD138 and IgD/
IgM (for gating controls see ESM Fig. 3) expression (IgM on
VH125.hCD20/NOD B cells, as the VH125 transgene is IgM
and VH125.hCD20/NOD mice do not express IgD). The per-
centage of splenic B cells (Fig. 3b) expressing CD138 was
less than in islet B cells (Fig. 3c) in both NOD and
VH125.hCD20/NOD mice. We detected more CD138+ B
cells in NOD mouse islets compared with VH125.hCD20/
NOD mouse islets, although the difference was not statistical-
ly significant (p = 0.09) (Fig. 3c,d). We observed few plasma
cells, defined by high expression of CD138 and loss of IgD/M
(Fig. 3c, red gate). CD138hiIgD/Mlo cells expressed Blimp-1,
a key transcription factor for plasma-cell differentiation [28],
displayed increased CD43 expression [29] and expressed
MHC II molecules (Fig. 3c, red histograms). Although pro-
portions were small, significantly fewer CD138hiIgD/Mlo B
cells were found in VH125.hCD20/NOD islets, compared
with NOD islets (Fig. 3d, p < 0.05). CD138intIgD/M+ cells
had a similar profile to the CD138− population (Fig. 3c,
orange gate vs blue gate).
Single-cell analysis, using imaging flow cytometry, was
performed in NOD mice to confirm our observations (Fig.
3e–i). The CD138int cells (Fig. 3f, orange/grey gate) were a
heterogeneous population that still expressed B220+ but had a
reduced (or had lost) CD19 and IgD expression (Fig. 3g). We
demonstrated that CD138hiIgDlo cells (Fig. 3f, red gate,)
expressed Blimp-1, although even in this small population,
heterogeneity was visible, as not all cells had lost B220 (Fig.
3g). CD138int and CD138hi populations displayed significant-
ly increased cell size (measured by area), compared with
CD138− populations (Fig. 3i). We showed a larger expanse
of cytoplasm synonymous with plasma cells, by bright-field
imaging. These findings indicated that some B cells, upon
entering pancreatic islets, progress into the plasma-cell path-
way, althoughmost exist as heterogeneous early-differentiated
plasma-cell populations.
Anti-insulin B cells in pancreatic tissue are enriched in the
CD138int subset We next questioned whether islet anti-insulin
B cells were present in the compartments shown in Fig. 3. Islet
anti-insulin B cells may already have endogenous insulin bound
to their BCRs. To ensure that we were detecting all anti-insulin B
cells, islets from groups of mice were pooled and incubated with
insulin–FITC at 37°C. We observed an increased frequency of
anti-insulin B cells compared with islets stained at 4°C (Fig. 4a).
Two insulin-specific populations were identified: insulin+CD19+
and insulin+CD19− B cells (Fig. 4a). We detected increased pro-
portions of insulin+CD19+ B cells in VH125.hCD20/NODmice
compared with NOD mice, with variability in both strains (Fig.
4b,c). We also demonstrated increased insulin+CD19+ cells in
pancreatic islets, compared with spleen, in both strains (Fig.
4b,c), supporting earlier observations (Fig. 2). Competitive bind-
ing experiments confirmed that both insulin+CD19+ and
insulin+CD19− populations were insulin specific (ESM Fig.
2a,b). To study expression of CD138 and IgD/IgM, we used
the gating strategy shown in Fig. 3. Insulin+CD19+ and
insulin+CD19− cells expressed intermediate CD138 in
VH125.hCD20/NOD and NOD strains (Fig. 4d–f). We found a
higher proportion of plasma cells (CD138hiIgM/Dlo) among the
insulin+CD19− population. Differences between the mice were
highlighted by a higher proportion of the insulin+CD19+ cells in
the CD138− fraction (Fig. 4d, blue gate, p< 0.001) and a lower
proportion in the CD138int fraction (Fig. 4d, orange gate,
p < 0.01) in the VH125.hCD20/NOD mice. The converse rela-
tionship was found in NOD mice (Fig. 4d; blue gate, p < 0.05;
orange gate, p< 0.001).
To evaluate cell morphology, we used single-cell imaging.
Spleens and pooled islets from VH125.hCD20/NOD mice
(ESM Fig. 4) were analysed alongside pooled NOD mouse
islets. Gating on live CD3−CD11c−CD11b− revealed anti-
insulin B cell populations divided by their CD19 expression
(Fig. 4g–j). We confirmed that anti-insulin B cells were
enriched in the CD138 subset. Insulin+CD19− cells also
displayed loss of IgD and little expression of Blimp-1 (Fig.
4k), supporting the observation that very few cells in the
CD138hiIgDlo population bound insulin. We demonstrated
that CD138 staining intensity was significantly increased in
the insulin+CD19− B cell population, compared with the
CD19+ population (Fig. 4l). However, some insulin+CD19+
B cells displayed increased CD138 expression, when com-
pared with the intensity of the CD138− B cell subset (Fig.
4m, dotted line), but insulin+CD19− B cells displayed signif-
icantly greater expression (Fig. 4l). Finally, cell size analysis
revealed that both of the insulin-positive populations were
larger compared with CD19+ insulin-negative B cells, indicat-
ing that these cells were activated and blasting (Fig. 4n).
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Fig. 3 Established pancreatic islet B cell infiltration is enriched for
CD138 but few of the cells express Blimp-1. Pancreatic islets from groups
(n = 2 or 3) of NOD and VH125.hCD20/NOD (VH125.hCD20) mice
were pooled, and B cells were analysed by flow cytometry. (a)
Representative flow plots to show islet B cells expressing IgD, IgM,
CD11b and CD5 from NODmice (black) and VH125.hCD20/NODmice
(grey), gated on l ive CD3−CD19+. (b–d ) Gating on l ive
CD3−CD11b−CD11c− revealed four different populations based on
CD138 and IgD/M expression: CD138− (blue gate); CD138intIgD/M+
(orange gate); CD138intIgD/Mlo (grey gate) and CD138hiIgD/Mlo (red
gate). Representative flow cytometry plots on splenocytes (b) and pan-
creatic islets (c) from NOD and VH125.hCD20/NOD mice; histograms
reveal various surface markers and Blimp-1 transcription factor
expression on each population. Overall percentages of different CD138
and IgD/M populations in NOD and VH125.hCD20/NOD mice are
shown in (d). *p < 0.05 (Mann–Whitney U test), n = 4 groups. (e, f)
Scatter gating for imaging flow cytometry, showing ‘dump’ channel (yel-
low) of live CD3−CD11b−CD11c− gate (e) and CD138+ and IgD+ NOD
islet populations (f). In (f): CD138−, blue; CD138intIgD+, orange;
CD138intIgDlo, grey; CD138hiIgDlo, red. (g) Representative images of
single cells from CD138−, CD138int and CD138hiIgDlo NOD islet B cell
populations. Scale bars, 7 μm. (h, i) CD138 intensity (h) and cell size
measured by area (i) on CD138−, CD138int and CD138hiIgDlo subsets
(n = 2 groups). Data are representative of at least two independent exper-
iments. Horizontal lines represent median values. ***p < 0.001 (one-way
ANOVA)
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Anti-insulin B cells are recruited to pancreatic islets after anti-
CD20 treatment B cell depletion therapy has been successful
in delaying the onset of diabetes [2, 3, 30]. However, the effect
of global B cell depletion on anti-insulin B cells has not been
studied.We confirmed that expression of VH125 had no effect
on hCD20 expression (ESM Fig. 5a) and that hCD20-
expressing B cells were present in the tissues examined
(ESM Fig. 5b). We treated groups of 6- to 8-week-old
VH125.hCD20/NOD mice with anti-CD20 mAb, and
analysed spleen and PLN tissue for anti-insulin B cells after
treatment. Expression of hCD20 was similar in anti-insulin
and non-insulin-binding B cells, with successful targeting of
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both populations in spleen (ESM Fig. 5c) and PLNs at 24 h
after treatment (ESM Fig. 5d). In agreement with previous
studies [31, 32], expression of murine CD20 was parallel with
the expression of human CD20 (ESM Fig. 5e). These results
suggest that autoreactive B cells in the periphery are success-
fully depleted and not spared by anti-CD20 treatment.
As anti-insulin B cells are altered upon entry into islets, we
investigated whether these cells would be targeted. We con-
firmed that IgM+ B cells were targeted by treatment (ESM
Fig. 6a), which we determined was a result of hCD20 expres-
sion (ESM Fig. 6b). CD19+insulin+ B cells were successfully
depleted, although cell numbers were low, making it difficult to
determine statistical significance (ESMFig. 6c,e). However, we
observed hCD20 expression on CD19+insulin+ B cells (ESM
Fig. 6d), indicating that anti-insulin B cells are targeted in pan-
creatic islets. Again, we found that hCD20 expression was par-
allel with murine CD20 on islet B cells (ESM Fig. 6b,d).
Conversely, hCD20 was not expressed on insulin+CD19−
B cells, indicating that these cells would be spared by
anti-CD20 treatment (ESM Fig. 6d). During the 12 week
observation period, 48% of the control anti-CD20 antibody-
treated mice became diabetic compared with 15% of the
2H7-treated mice.
To investigate the repopulation of anti-insulin B cells, we
examined CD19+insulin+ and CD19+insulin− cells at 8 and
12 weeks after depletion (Fig. 5). In hCD20/NOD mice, B
cells repopulate peripheral tissues by 12 weeks post treatment
[2, 19]. We found repopulation dynamics were similar for
anti-insulin B cells in spleen (Fig. 5a–g) and PLNs in
VH125.hCD20/NOD mice (Fig. 5b–h). However, we ob-
served that anti-insulin B cells repopulated earlier than non-
insulin B cells in pancreatic islets (Fig. 5i).
To analyse anti-insulin B cells further, we pooled
pancreases to gain more cells for analysis (Fig. 6).
Considering that anti-insulin B cells are enriched in the
CD138int fractions (Fig. 4), we analysed IgM and CD138
subpopulations after 12 weeks of treatment. Islet B cells ex-
pressing IgM were reduced in 2H7-treated mice (Fig. 6a,b),
although interestingly an increase in the CD138intIgMlo frac-
tion was observed (Fig. 6b). In line with this, we observed an
increase in the percentage of insulin+CD19− cells (Fig. 6c,d),
which were significantly enriched in the CD138intIgMlo frac-
tion (Fig. 6e–g) after anti-CD20 treatment.
Discussion
In this study, we describe novel anti-insulin B cell populations
that reside in the pancreatic islets during type 1 diabetes
development. Anti-insulin B cells are selectively recruited to
pancreatic tissue during diabetes progression and upon
entry these cells assume a unique CD138int phenotype.
Furthermore, for the first time, we show that during global B
cell depletion, anti-insulin B cells are not spared but are
targeted in VH125.hCD20/NOD mice and, importantly, we
have identified a key pattern of repopulation after resetting
the B cell repertoire. This work highlights the need to further
understand the dynamics of anti-insulin B cells.
Previous work performed in VH125Tg and VH125
SDNOD
mouse models supports the notion that anti-insulin B cells are
functionally active, respond to mitogens and are effective
APCs despite their tolerant state [7, 11, 33]. Here, we show
that anti-insulin B cells from our VH125.hCD20/NODmouse
model successfully present antigen to insulin-specific CD8 T
cells. Consequently, anti-insulin B cells not only present to
CD4 T cells [11] but also successfully present to pathogenic
insulin-specific CD8 T cells.
Insulin-reactive B cells escape immune tolerance in mice
susceptible to type 1 diabetes [8]. Indeed, we show that anti-
insulin B cells are selectively recruited to pancreatic tissue in
VH125.hCD20/NOD mice. Our data supports a previous
study, using a different method of detection (insulin-specific
mAb123-biotin), showing increased insulin-binding B cells in
the pancreas of VH125Tg/NODmice [15].While we have not
addressed whether anti-insulin B cells are specifically recruit-
ed via a chemokine receptor, it is conceivable that anti-insulin
B cells express high levels of C-X-C motif chemokine recep-
tor 3 (CXCR3), a chemokine receptor involved in recruitment
Fig. 4 Anti-insulin islet B cells are enriched in the CD138int subset.
Pancreatic islets from groups (n = 2 or 3) of NOD and VH125.hCD20/
NOD (VH125.hCD20) mice were pooled and insulin+ B cells were
analysed by flow cytometry. (a) Representative flow plots showing
insulin-positive B cells in spleen and islets, either stained at 4°C or
37°C, against CD19 expression in NOD and VH125.hCD20/NOD
mice. (b, c) Line graphs represent percentages of insulin-positive B
cells from spleens and islet that were detected by staining at 37°C in
NOD (b) and VH125.hCD20/NOD mice (c) (n = 4 groups). (d) Four
different populations express different combinations of CD138 and IgD
inNODmice and IgM inVH125.hCD20/NODmice: CD138−IgD+/IgM+
(blue); CD138intIgD+/IgM+ (orange); CD138intIgDlo/IgMlo (grey) and
CD138hiIgDlo/IgMlo (red). (e, f) Percentage of insulin+CD19+ and
insulin+CD19− enrichment categorised by CD138 and IgM in
VH125.hCD20 mice (e) and IgD subsets in NOD mice (f) (n = 3
groups). *p < 0.05, **p < 0.01 and ***p < 0.001 (two-way ANOVA).
(g–j) Scatter gating for imaging flow cytometry on NOD islets that
were pulsed with insulin–FITC at 37°C, showing: ‘dump’ channel (red
with orange outline) of live CD3−CD11b−CD11c− gate (g); B220 and
CD19 expression on CD3−CD11b−CD11c− cells (red) (h); CD138 and
Blimp-1 defined populations (CD138−, blue; CD138int, orange; CD138hi,
red) (i); and CD19− (green) and CD19+ (purple) insulin+ B cells (j).
(k) Representative single-cell images from NOD islet insulin+CD19+,
insulin+CD19− and insulin−CD19+ B cell populations. Scale bars, 7
μm. (l, m) CD138 staining intensity (l) and CD138 intensity/CD138−
intensity ratio (m) on insulin+CD19+ and insulin+CD19− B cell
populations. ***p < 0.001 (Mann–Whitney U test). (n) Cell size
measured by area on insulin+/− B cell populations (n = 2 groups).
**p < 0.01 and ***p < 0.001 (one-way ANOVA). Data are
representative of at least two independent experiments. Horizontal red
and black lines represent median values
R
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of lymphocytes in autoimmunity [34, 35]. High levels of
CXCR3 are expressed on other autoreactive B cell subsets
[36] and CXCR3 is involved in localisation of plasma cells
[37]. Further investigation is required to fully understand
whether the enrichment observed is a result of recruitment or
retention.
We reveal that anti-insulin B cells are unique, although
heterogeneous, in pancreatic islets, with enrichment of
CD138 and loss of their naive BCR isotypes (IgM/IgD).
This suggests that some B cells enter the plasma-cell
differentiation pathway. Although the expression of CD138
on pancreatic islet B cells has been described previously
[27], and more recently on insulin-binding B cells in
VH125.NODmice [26], this is the first time the heterogeneity
has been reported. Furthermore, CD138 intermediate expres-
sion coupled with a lack of Blimp-1 demonstrates that islet B
cells are not terminally differentiated. This does not exclude
the possibility that CD138hi B cells have previously expressed
an insulin-specific BCR but lost the BCR on terminal differ-
entiation, [38, 39] so are unable to detect and bind insulin.
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Fig. 5 Anti-insulin B cells repopulate pancreatic islets more rapidly than
insulin-negative B cells after anti-CD20 treatment. Groups of
VH125.hCD20/NOD mice, aged 6–8 weeks old, were injected with
2H7 anti-CD20 or IgG isotype control. Spleen, PLNs and pancreatic islets
were analysed for insulin-positive and insulin-negative B cells at 8 weeks
and 12 weeks post depletion by flow cytometry. (a–f) No. of cells from
IgG control-treated (black circles) and 2H7-treated (grey squares) mice
for insulin-negative B cells (a–c) and insulin-positive B cells (d–f) from
spleen (a, d) PLNs (b, e) and islets (c, f). (g–i) Percentage of B cells
repopulated at 8 and 12 weeks after treatment from spleen (g), PLNs
(h) and islets (i) of mice shown in (a–f). Percentages were calculated as
individual numbers from each 2H7-treatedmouse / mean number from all
IgG control antibody-treated mice. Horizontal lines represent the median
value. Data represent three independent experiments. At 8 weeks, n = 7
(spleen), n = 7 (PLNs) and n = 9 (islets) for control IgG-treated mice and
n = 10 (spleen), n = 9 (PLNs) and n = 12 (islets) for 2H7-treated mice. At
12 weeks, n = 8 (spleen), n = 6 (PLNs) and n = 7 (islets) for control IgG
and n = 11 (spleen), n = 7 (PLNs) and n = 11 (islets) for 2H7-treated mice.
*p < 0.05 (one-way ANOVA)
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CD138hiIgDlo B cells remain MHC II positive. However, as
MHC II is lost on terminally differentiated B cells, these islet
CD138hiIgDlo B cells may also represent an early differenti-
ated plasma-cell type [37] or a short-lived plasma-cell [40].
While loss of BCR expression would render B cells unrespon-
sive to antigen, expression of MHC II would still allow
antigen presentation in an inflammatory microenvironment,
possibly driving beta cell destruction. Intermediate expression
of CD138 is reminiscent of autoreactive anti-sm (ribonucleo-
protein Smith) B cells described in the spleen of autoim-
mune mice [41]. However, some CD138int anti-insulin B cells
that are still IgD competent may resemble IgMlowIgDhigh ma-
ture follicular B cells, a unique splenic follicular zone subset
[42]. It is clear CD138int and CD138hi are distinct populations,
and their relationship and role in auto-inflammation is yet to
be defined.
We note that wild-type NOD islet B cells resemble the BND
(anergic naive) compartment in peripheral blood of humans,
which are also IgMlowIgD+ in phenotype. This anergic BND
compartment is enriched with a pool of autoreactive B cells
[43]. However, these BND cells are lost in individuals with
newly diagnosed type 1 diabetes [24] for reasons that are
currently unclear. Our data support the notion that these B
cells may have relocated to pancreatic islets and are thus lost
from peripheral blood. Interestingly, co-expression of IgD and
IgM promotes accumulation of anergic B cells and increased
CD138 expression is associated with reduced IgM [44].
Furthermore, a loss of IgD expression on B cells induces
amplified CD138 expression [44], possibly reflecting the
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Fig. 6 CD138int anti-insulin B
cells are enriched in pancreatic
islets after anti-CD20 treatment.
Groups of 6- to 8-week-old
VH125.hCD20/NOD mice were
injected with 2H7 anti-CD20 or
IgG isotype control. Groups of
mice (n = 2 or 3 per group) were
pooled and insulin+ B cells from
pancreatic islets were analysed for
four different populations based
on CD138 expression: CD138−
(blue); CD138intIgM+ (orange);
CD138intIgMlo (grey) and
CD138hiIgMlo (red). (a, b)
Representative flow plots
showing gating on live
CD3−CD11b−CD11c− (a) and
graph showing the overall
percentages of the four different
populations (b). (c, d)
Representative flow plots
showing insulin−CD19+,
insulin+CD19+ and
insulin+CD19− cells (c) and graph
showing the overall percentages
of these cells (d); 2H7 (black
circles), IgG (grey circles). (e)
Representative flow plots
showing CD138 and IgM
expression in insulin+CD19+ and
insulin+CD19− cells. (f, g) Graphs
showing CD138 and IgM
populations on insulin+CD19+ (f)
and insulin+CD19− cells (g) (n = 5
groups for control IgG treatment;
n = 4 groups for 2H7 treatment).
Horizontal lines represent the
median values. Data represent
two independent experiments.
*p < 0.05 (one-way ANOVA)
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response of anti-insulin B cells entering pancreatic tissue. In
humans, CD138+ B cells have been detected in islets that are
positive for CD20+ B cells in five out of 29 individuals studied
[45, 46]. This suggests either that there are similar migration
patterns in human pancreatic islets or that B cells change in
situ, the latter being consonant with our observations.
Our work in this diabetes model is consistent with earlier
studies in arthritis [32] showing successful depletion of
peripheral autoreactive B cells using an hCD20 transgenic
system. While a previous study suggested that all B cells
downregulate CD20 upon islet entry [27], we show this is
not the case and that a heterogeneous population exists, which
includes CD20+ B cells. This disparity may be due to the
different anti-CD20 mAb used. We detected some anti-
insulin B cells that had lost CD20 expression and were spared
from anti-CD20 treatment. However, this population is small
and diabetes is delayed in a large proportion ofmice and hence
anti-CD20 treatment is clearly beneficial, at least temporarily.
The early insulin-positive B cell recruitment to pancreatic
islets after anti-CD20 treatment is an important observation in
the therapeutic use of B cell depletion. We demonstrate that
insulin+CD19−B cells are increased in the pancreatic environ-
ment upon repopulation, indicating that during repopulation,
pancreas-infiltrating anti-insulin B cells are recruited earlier
and enter the plasma-cell differentiation pathway more rapid-
ly. Alternatively, B cells (developing B cells [47]) already
expressing CD138 in the bone marrow exit prematurely after
anti-CD20 treatment and track to pancreatic islets. Anti-CD20
treatment alters the islet microenvironment [19] and may
allow CD19− anti-insulin B cells to proliferate in situ or
receive increased survival signals. B cell activating factor
(BAFF) improves the survival rate of autoreactive B cells
[48] and increased BAFF levels are seen in individuals after
B cell depletion therapy [49, 50]. Factors such as BAFF may
influence the return of the autoreactive B cell repertoire and
allow anti-insulin B cells to populate pancreatic tissue follow-
ing anti-CD20 treatment.
The function of both CD138int populations is of impor-
tance, particularly the enriched insulin+CD19− observed after
anti-CD20 treatment. These cells may be functionally altered
and may change the pancreatic environment. Whether early
recruitment of anti-insulin B cells to the pancreas after global
B cell depletion contributes to disease persistence or, alterna-
tively, may in some way participate in the delay of diabetes
needs to be addressed. This latter possibility is of particular
interest, as recently CD138 (syndecan 1) has been identified
as a hallmark of anergy [44]. It should also be considered that
the insulin+ B cells we have defined have opposing roles. We
acknowledge that while we would like to test these possibili-
ties, functional assays on such small populations is highly
technically challenging and would require many pancreas
samples to be pooled from large numbers of experimental
animals for each group, rendering this unfeasible with current
technology. However, this would be an important investiga-
tion for the future. Nevertheless, our study highlights a unique
phenotype of islet-infiltrating B cells, emphasising the need
for greater understanding of autoreactive B cells and how they
promote the development of type 1 diabetes, as well as pro-
viding novel insight to help with better design of more effec-
tive immunotherapies.
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